Literature DB >> 17120004

Ocular penetration of caspofungin in a rabbit uveitis model.

David Goldblum1, Kathrin Fausch, Beatrice E Frueh, Regula Theurillat, Wolfgang Thormann, Stefan Zimmerli.   

Abstract

BACKGROUND: Little is known about the ocular penetration of echinocandin antifungals. We studied the ocular distribution of systemically administered caspofungin in a rabbit uveitis model.
METHODS: Caspofungin (1 mg/kg per day) was given intravenously to rabbits as a single dose or as repeated daily doses on 7 days starting 24 h after induction of unilateral uveitis by intravitreal endotoxin injection. Caspofungin concentrations were determined by high-performance liquid chromatography in the cornea, aqueous humor, vitreous humor, and serum 4, 8, 16, and 24 h after administration of a single dose and 24 h after the last of seven doses.
RESULTS: The mean caspofungin concentration in the aqueous of the inflamed eye 4 and 8 h after single-dose administration was 1.30 +/- 0.39 microg/ml and 1.12 +/- 0.34 microg/ml, respectively. Drug concentrations decreased to 0.24 +/- 0.09 microg/ml at 16 h and 0.26 +/- 0.14 microg/ml at 24 h. In the vitreous of inflamed eyes drug levels were undetectable at all time points. No drug was found in the aqueous of inflamed eyes 24 h after the last of seven repeated doses, and the vitreous only contained trace amounts. In the corneas of inflamed eyes concentrations reached 1.64 +/- 0.48 microg/g at 4 h, peaked at 2.16 +/- 1.14 microg/g at 8 h, and declined to 1.87 +/- 0.52 microg/g and 1.49 +/- 0.48 microg/g at 16 and 24 h, respectively. After repeated dosing, corneal concentrations of caspofungin were 0.8 and 1.0 microg/g and below the limit of detection in two of four animals. In non-inflamed eyes no drug was detectable in the aqueous and vitreous humor, and the corneas at any time point.
CONCLUSIONS: In our model, caspofungin reached therapeutically relevant levels in the aqueous and cornea but not in the vitreous humor of inflamed eyes. Intraocular drug deposition was critically dependent on a disrupted blood-eye barrier. These findings suggest a limited role for caspofungin in the treatment of fungal endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17120004     DOI: 10.1007/s00417-006-0460-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  27 in total

1.  Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection.

Authors:  C M Chavez-Eng; M Schwartz; M L Constanzer; B K Matuszewski
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-01-22

2.  Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.

Authors:  G M Gauthier; T M Nork; R Prince; D Andes
Journal:  Clin Infect Dis       Date:  2005-06-28       Impact factor: 9.079

3.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.

Authors:  T J Walsh; J Bacher; P A Pizzo
Journal:  Lab Anim Sci       Date:  1988-08

4.  Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model.

Authors:  David Goldblum; Beatrice E Frueh; Gian-Marco Sarra; Konstantinos Katsoulis; Stefan Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin.

Authors:  Marlene L Durand; Ivana K Kim; Donald J D'Amico; John I Loewenstein; Ellis H Tobin; Shalom J Kieval; Stephen S Martin; Dimitri T Azar; Frederick S Miller; Brandon J Lujan; Joan W Miller
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

Review 6.  The spectrum of orbital aspergillosis: a clinicopathological review.

Authors:  L A Levin; R Avery; J W Shore; J J Woog; A S Baker
Journal:  Surv Ophthalmol       Date:  1996 Sep-Oct       Impact factor: 6.048

7.  Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Authors:  Eduardo G Arathoon; Eduardo Gotuzzo; L Miguel Noriega; Rayanne S Berman; Mark J DiNubile; Carole A Sable
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 8.  Survival factors in rhino-orbital-cerebral mucormycosis.

Authors:  R A Yohai; J D Bullock; A A Aziz; R J Markert
Journal:  Surv Ophthalmol       Date:  1994 Jul-Aug       Impact factor: 6.048

9.  Comparison of caspofungin and amphotericin B for invasive candidiasis.

Authors:  Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

Review 10.  The first echinocandin: caspofungin.

Authors:  O A Cornely; Karina Schmitz; Sabine Aisenbrey
Journal:  Mycoses       Date:  2002       Impact factor: 4.377

View more
  14 in total

1.  Rapid and sensitive liquid chromatography/mass spectrometry assay for caspofungin in human aqueous humor.

Authors:  Chin Fen Neoh; Hui He; Jian Li; Robert O Fullinfaw; Lok Leung; Anant Misra; Rasik B Vajpayee; Geoffrey E Davies; Kay Stewart; David C M Kong
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

2.  Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye.

Authors:  Deb K Mojumder; Francis A Concepcion; Shil K Patel; Andrew J Barkmeier; Petros E Carvounis; John H Wilson; Eric R Holz; Theodore G Wensel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-26       Impact factor: 4.799

3.  Stability of extemporaneously prepared 0.5-percent caspofungin eye drops: a potential cost-savings exercise.

Authors:  Chin Fen Neoh; Jovan Jacob; Lok Leung; Jian Li; Angela Stathopoulos; Kay Stewart; David C M Kong
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

4.  The distribution of Mn2+ in rabbit eyes after topical administration for manganese-enhanced MRI.

Authors:  Shenzhi Liang; Miao Liang; Yu Zhu; Jingliang Cheng; Zitao Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

5.  Penetration of topically administered 0.5-percent caspofungin eye drops into human aqueous humor.

Authors:  Chin Fen Neoh; Lok Leung; Anant Misra; Rasik B Vajpayee; Geoffrey E Davies; Robert O Fullinfaw; Kay Stewart; David C M Kong
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

6.  Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives.

Authors:  M Kernt; A Kampik
Journal:  Clin Ophthalmol       Date:  2010-03-24

7.  Intraocular penetration of intravenous micafungin in inflamed human eyes.

Authors:  Kiyofumi Mochizuki; Akira Sawada; Shinsuke Suemori; Hideaki Kawakami; Yoshiaki Niwa; Yuji Kondo; Kiyofumi Ohkusu; Noriaki Yamada; Shinji Ogura; Takashi Yaguchi; Kazuko Nishimura; Satoshi Kishino
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

Review 8.  Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors:  Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

9.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

10.  Pharmacokinetics and efficacy of intraocular flurbiprofen.

Authors:  S Blazaki; C Tsika; M Tzatzarakis; E Naoumidi; A Tsatsakis; C Tsatsanis; Miltiadis K Tsilimbaris
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-09-29       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.